Physician profile
Segundo Imbert
NPI 1013961291
$6,886.71
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $818 · 2021: $1,175 · 2022: $1,605 · 2023: $1,524 · 2024: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.53 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,099.38 | 2019-2024 | Rexulti, Nuedexta |
| Abbvie INC. | $1,063.18 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $415.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $372.31 | 2019-2024 | Spravato |
| Corium, LLC | $339.17 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $295.07 | 2019-2024 | Trintellix |
| Validus Pharmaceuticals LLC | $275.21 | 2019-2024 | Equetro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.06 | 2020-2023 | |
| Bausch Health US, LLC | $232.79 | 2019-2024 | Wellbutrin, Aplenzin |
| Vanda Pharmaceuticals INC. | $229.35 | 2019-2024 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $210.39 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $202.13 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $194.05 | 2019-2023 | Lybalvi, Aristada |
| Lundbeck LLC | $174.65 | 2019-2022 | |
| Allergan, INC. | $172.31 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $156.22 | 2019-2022 | |
| Neuronetics, INC. | $152.35 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $136.78 | 2020-2024 | Ingrezza |
| Jazz Pharmaceuticals INC. | $132.79 | 2020-2022 | |
| Neos Therapeutics, Lp | $126.95 | 2019-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $125.88 | 2021-2024 | Jornay Pm |
| Eisai INC. | $105.29 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $103.31 | 2021-2023 | Qelbree |
| Shire North American Group INC | $68.41 | 2019 | |
| Tris Pharma INC | $63.64 | 2019-2024 | Dyanavel Xr |
| Alfasigma USA, INC. | $46.89 | 2020-2021 | |
| Adlon Therapeutics L.P. | $44.55 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $25.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.73 | 2019-2020 | |
| Noven Therapeutics, LLC | $22.81 | 2023 | Xelstrym |
| Harmony Biosciences LLC | $21.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.23 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Segundo Imbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.